UCB SA (UCBJY)
OTHER OTC:UCBJY
Want to see UCBJY full AI Analyst Report?
Top Page
UCB SA
(OTC:UCBJY)
Select Model
Select Model
Rating:68Neutral
Price Target:
$148.00
▼(-5.06% Downside)
Action:DowngradedDate:03/04/26
The score is supported primarily by solid financial performance (notably stronger 2025 cash generation and improved leverage) and a positive earnings outlook with growth and margin expansion guidance. These are partially offset by weak current technical momentum and a relatively high P/E with a modest dividend yield.
Positive Factors
Sustained Revenue Growth
Material top-line expansion in 2025 reflects durable commercial traction across core franchises and scale in key markets. A stronger revenue base improves funding for R&D and marketing, reduces single-year execution risk, and underpins multi-year growth expectations if core products keep gaining share.
Negative Factors
Margin Pressure / EBIT Decline
Declining operating profit despite rising sales signals margin compression from higher operating costs or mix shifts. If persistent, this erodes operating leverage, reduces incremental free cash generation from new sales and constrains the company’s ability to fund pipeline or absorb pricing headwinds over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Material top-line expansion in 2025 reflects durable commercial traction across core franchises and scale in key markets. A stronger revenue base improves funding for R&D and marketing, reduces single-year execution risk, and underpins multi-year growth expectations if core products keep gaining share.
Read all positive factors
UCB SA (UCBJY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.50B
Dividend Yield0.55%
Average Volume (3M)2.85K
Price to Earnings (P/E)30.2
Beta (1Y)0.49
Revenue Growth31.78%
EPS Growth54.49%
CountryUS
Employees9,052
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.08
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue5.64
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda16.74
Forecast
1Y Price Target
$175.00Price Target Upside12.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)6.3
Revenue Forecast (FY)$9.94B
UCB SA Business Overview & Revenue Model
Company Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial ...
How the Company Makes Money
UCB makes money primarily by selling prescription medicines. Its revenue is largely generated from net product sales of branded therapies to wholesalers, pharmacies, hospitals, and other healthcare providers/distributors across major markets (nota...
UCB SA Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 23, 2026
Earnings Call Sentiment Positive
The call presented a broadly positive operational and financial story: strong top-line growth, meaningful margin expansion, doubled EPS, sizable commercial traction for BIMZELX and other growth drivers, important regulatory wins (KYGEVVI) and pipeline momentum. Challenges noted include net-price/gross-to-net pressure as access expands, near-term LOE for BRIVIACT, industry headwinds in clinical trials and competitive risks in several programs. On balance the positives (robust growth, profitability, pipeline progress and a strengthened balance sheet) outweigh the challenges, although execution on pricing, trial execution and competitive positioning will be important in 2026.Positive Updates
Strong Top-Line Growth
Total revenues of EUR 7.7 billion in FY2025, up 26% (29% at constant exchange rates); net sales near EUR 7.4 billion, up 32% (35% at constant exchange rates).
Negative Updates
Pricing Pressure and Gross-to-Net Dynamics
H2 2025 true-up on BIMZELX gross-to-net amounted to ~5% of total BIMZELX; company expects net price decreases as U.S. access expands and more scripts become rebated, weighing on net pricing despite volume growth.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Top-Line Growth
Total revenues of EUR 7.7 billion in FY2025, up 26% (29% at constant exchange rates); net sales near EUR 7.4 billion, up 32% (35% at constant exchange rates).
Read all positive updates
Company Guidance
UCB guided 2026 revenue growth of high-single-digit to low-double-digit at constant exchange rates (building off 2025’s €7.7bn total revenues and ~€7.4bn net sales, +32% YoY) and EBITDA growth of high-single-digit to high‑teens at CER — or, starting from an adjusted 2025 EBITDA base of €2.4bn, growth in the high‑teens to high‑20s % at CER — driven by the five growth drivers (BIMZELX, RYSTIGGO, ZILBRYSQ, FINTEPLA, EVENITY), continued gross‑margin improvement despite net‑price pressure (2025 adjusted gross profit €6.1bn; gross margin 79.2%), rising marketing & selling and R&D spend (M&S €2.5bn; R&D €1.8bn, 24% of revenues) with tight G&A control, an expected tax rate around ~20% (versus a 14% effective rate in 2025), guidance given at constant exchange rates excluding MFN/tariff impacts, and no planned established‑brand disposals this year.UCB SA Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
76
Positive
Cash Flow
82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.44B | 6.15B | 5.25B | 5.52B | 5.78B |
| Gross Profit | 5.29B | 4.40B | 3.54B | 3.84B | 4.34B |
| EBITDA | 1.72B | 1.96B | 1.28B | 1.17B | 1.59B |
| Net Income | 1.50B | 1.06B | 343.00M | 418.00M | 1.06B |
Balance Sheet | |||||
| Total Assets | 18.15B | 17.35B | 15.54B | 15.87B | 14.21B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.76B | 923.00M | 1.14B | 1.48B |
| Total Debt | 2.24B | 3.03B | 3.04B | 2.90B | 2.12B |
| Total Liabilities | 7.29B | 7.32B | 6.56B | 6.80B | 5.82B |
| Stockholders Equity | 10.86B | 10.03B | 8.97B | 9.06B | 8.39B |
Cash Flow | |||||
| Free Cash Flow | 1.81B | 920.00M | 445.00M | 748.00M | 1.06B |
| Operating Cash Flow | 2.08B | 1.24B | 761.00M | 1.12B | 1.55B |
| Investing Cash Flow | -373.65M | 282.00M | -440.00M | -1.58B | -487.00M |
| Financing Cash Flow | -1.04B | -818.00M | -308.00M | 70.00M | -1.12B |
UCB SA Technical Analysis
Positive
155.89
Price Trends
153.05
Positive
148.72
Positive
135.28
Positive
Market Momentum
2.06
Negative
54.33
Neutral
29.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UCBJY, the sentiment is Positive. The current price of 155.89 is above the 20-day moving average (MA) of 151.80, above the 50-day MA of 153.05, and above the 200-day MA of 135.28, indicating a bullish trend. The MACD of 2.06 indicates Negative momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 29.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UCBJY.
UCB SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $28.54B | 21.65 | 11.89% | 2.23% | 5.05% | -7.01% | |
75 Outperform | $73.52B | 27.62 | 14.32% | 0.45% | 5.92% | 1.85% | |
75 Outperform | $48.47B | 14.76 | 16.82% | ― | 90.23% | 51.88% | |
68 Neutral | $51.50B | 30.22 | 15.16% | 0.55% | 31.78% | 54.49% | |
63 Neutral | $39.51B | 53.36 | 90.35% | ― | 82.57% | ― | |
54 Neutral | $24.51B | -17.95 | -6.03% | ― | 11.42% | -73.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
UCBJY
UCB SA
136.03
39.82
41.38%
ALNY
Alnylam Pharma
296.11
22.56
8.25%
REGN
Regeneron
701.42
101.12
16.84%
ARGX
Argenx Se
783.50
126.85
19.32%
BNTX
BioNTech SE
97.54
-3.56
-3.52%
RPRX
Royalty Pharma
49.47
17.24
53.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.